Fishbane Steven
SUNY at Stony Brook School of Medicine, USA.
Am J Kidney Dis. 2007 Jun;49(6):736-43. doi: 10.1053/j.ajkd.2007.03.007.
Iron deficiency has been studied extensively in patients with chronic kidney disease on hemodialysis therapy. However, few studies looked at iron treatment in the nondialysis chronic kidney disease population. Limited data suggest that iron deficiency is common in patients with chronic kidney disease with anemia; this lack of iron can hinder the effectiveness of erythropoiesis. The diagnosis of iron deficiency should involve clinical judgment, with an emphasis on clinical characteristics of the patient because of the limited amount of literature examining the interpretation of iron testing results. When iron deficiency is diagnosed in nondialysis patients with chronic kidney disease, a search must be initiated for any sources of blood loss. After addressing any blood loss, the preferred route of iron treatment must be determined. To date, no clear advantage was shown with intravenous versus oral administration in nondialysis patients, as shown in the hemodialysis setting. Thus, oral iron therapy may be a more reasonable option unless oral therapy previously failed. Additional research is needed to support evidence-based guidelines for the treatment of iron deficiency in the nondialysis chronic kidney disease population because this population differs from hemodialysis patients in the decreased extent of blood loss.
缺铁已在接受血液透析治疗的慢性肾病患者中得到广泛研究。然而,很少有研究关注非透析慢性肾病人群的铁剂治疗。有限的数据表明,缺铁在伴有贫血的慢性肾病患者中很常见;铁的缺乏会阻碍红细胞生成的有效性。由于研究铁检测结果解读的文献数量有限,缺铁的诊断应涉及临床判断,重点关注患者的临床特征。当在非透析慢性肾病患者中诊断出缺铁时,必须查找任何失血来源。解决任何失血问题后,必须确定铁剂治疗的首选途径。迄今为止,与血液透析患者不同,在非透析患者中,静脉给药与口服给药相比未显示出明显优势。因此,除非口服治疗先前失败,口服铁剂治疗可能是更合理的选择。需要更多研究来支持针对非透析慢性肾病人群缺铁治疗的循证指南,因为该人群与血液透析患者不同,失血程度有所降低。